A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
3상
완료
NCT06060457
| 대상 질환 | Respiratory Syncytial Virus |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | ModernaTX, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 1,900 명 |
|---|
| 중재(약물) | mRNA-1345, Fluzone HD |
|---|
| 시작일 | 2023년 9월 25일 |
|---|
| 완료일 | 2024년 6월 7일 |
|---|
| 결과 공개일 | 2025년 7월 30일 |
|---|
요약
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Within 7 days after Day 1 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 689 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 547 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection
Within 7 days after Day 22 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 251 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 557 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection
Up to 21 days after Day 1 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 72 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 72 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.